Holen Sie sich die Stockscreener-App
28.96
2.30%
0.65
Handel nachbörslich:
28.35
-0.61
-2.11%
Schlusskurs vom Vortag:
$28.31
Offen:
$28.6
24-Stunden-Volumen:
287.07K
Relative Volume:
0.73
Marktkapitalisierung:
$1.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.02%
1M Leistung:
+1.08%
6M Leistung:
+106.71%
1J Leistung:
+73.52%
1-Tages-Spanne:
$28.05
$29.93
1-Wochen-Bereich:
$26.60
$30.79
52-Wochen-Spanne:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
28.96 | 1.35B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
Can Rapport Therapeutics Inc. stock resist market sell offsWatch List & Consistent Income Trade Recommendations - ulpravda.ru
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials - Intellectia AI
Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2 - Nasdaq
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance
Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st
Form 424B5 Rapport Therapeutics, - StreetInsider
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program - TradingView — Track All Markets
Rapport Therapeutics Advances RAP-219 into Phase 3 Trials for Focal Onset Seizures, Expands Epilepsy Portfolio with New Program - Quiver Quantitative
Experimental epilepsy drug advances to big trial and adds new seizure target - Stock Titan
What technical charts say about Rapport Therapeutics Inc. stock2026 world cup usa national team qualification goalkeepers possession football odds analysis preview - ulpravda.ru
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? - AOL.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
How sustainable is Rapport Therapeutics Inc. stock dividend payoutWeekly Trade Review & Proven Capital Preservation Tips - Улправда
Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $172,890.12 in Stock - MarketBeat
Rapport Therapeutics CEO Sells Shares Worth Over $323K - TradingView — Track All Markets
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Selloffs & Daily Profit Maximizing Tips - Улправда
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $255,170.00 in Stock - MarketBeat
Rapport Therapeutics CSO Sells Shares Under Trading Plan - TradingView — Track All Markets
Rapport Therapeutics Earnings Notes - Trefis
Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans - Sahm
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
Rapport Therapeutics price target raised to $40 from $34 at HC Wainwright - MSN
Rapport Therapeutics, Inc. (RAPP) is up 9.03% in one week: What you should know - MSN
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):